Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 7/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30236727 | 1.00 | CA9 (0.45) | CA9CA12CA2CA1TSHR | |
| SCHEMBL10819148 | 0.89 | CA9 (0.38) | CA9CA12CA2CA1TSHR | |
| SCHEMBL24337169 | 0.86 | CA9 (0.46) | CA9CA12CA2CA1TSHR | |
| SCHEMBL22677465 | 0.86 | CA9 (0.50) | CA9CA12CA2CA1TSHR | |
| SCHEMBL8434120 | 0.86 | CA9 (0.50) | CA9CA12CA2CA1TSHR | |
| SCHEMBL8621491 | 0.86 | CA9 (0.50) | CA9CA12CA2CA1TSHR | |
| SCHEMBL9351909 | 0.86 | CA9 (0.50) | CA9CA12CA2CA1TSHR | |
| SCHEMBL22677480 | 0.86 | CA9 (0.50) | CA9CA12CA2CA1TSHR | |
| SCHEMBL15451491 | 0.85 | CA9 (0.36) | CA9CA12CA2CA1TSHR | |
| SCHEMBL21023260 | 0.83 | CA9 (0.44) | CA9CA12CA2CA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC. | 2018-06-07 | — | — | US | disclosed |
| US-8163551-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEATTLE GENETICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090317869-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEATTLE GENETICS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-5808018-A | Fluorine containing sialyl Lewis X derivatives and synthetic intermediates thereof | DAIKIN INDUSTRIES, LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5770407-A | Process for preparing nucleotide inhibitors of glycosyltransferases | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0811634-A1 | FLUORINATED SIALYL-LEWIS X DERIVATIVES AND INTERMEDIATES FOR SYNTHESIS THEREOF | DAIKIN INDUSTRIES, LIMITED (JP) | 1997-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155677-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | CA9 448/4885CA12 253/4885CA2 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.